Markets:

Overview

News

Currencies

International

Treasuries

ADC Therapeutics SA Common Shares (NY:ADCT)

3.405 -0.185 (-5.15%)

Streaming Delayed Price Updated: 12:41 PM EST, Jan 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ADC Therapeutics SA Common Shares

< Previous 1 2 3 4 5 6 7 8 Next >

Earnings Scheduled For March 3, 2022 ↗

March 03, 2022

Companies Reporting Before The Bell • Travelzoo (NASDAQ:TZOO) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban...

Via Benzinga

Earnings Preview For ADC Therapeutics ↗

March 02, 2022

ADC Therapeutics (NYSE:ADCT) is set to give its latest quarterly earnings report on Thursday, 2022-03-03. Here's what investors need to know before the announcement. Analysts...

Via Benzinga

ADC Therapeutics to Host Fourth Quarter and Year-End 2021 Financial Results Conference Call on March 3, 2022

February 24, 2022

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics Releases its Inaugural Environmental, Social and Governance Report

February 17, 2022

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics Highlights its Proprietary ADC Platform and Solid Tumor Pipeline

February 08, 2022

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics to Participate in Guggenheim Oncology Conference

February 02, 2022

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics to Host Webcast Highlighting its ADC Platform and Solid Tumor Pipeline on February 8, 2022

January 20, 2022

From ADC Therapeutics

Via Business Wire

ADC Therapeutics, Mitsubishi Tanabe Ink Zynlonta Licensing Pact In Japan ↗

January 18, 2022

ADC Therapeutics SA (NYSE: ADCT) has entered an exclusive license agreement with Mitsubishi Tanabe Pharma Corporation to develop and commercialize...

Via Benzinga

ADC Therapeutics Announces Exclusive License with Mitsubishi Tanabe Pharma Corporation to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Japan

January 18, 2022

From ADC Therapeutics SA

Via Business Wire

52 Biggest Movers From Friday ↗

January 18, 2022

Gainers Splash Beverage Group, Inc. (NASDAQ: SBEV) shares gained 118.9% to settle at $4.18 on Friday. Splash Beverage recently announced it has received authorization to sell its...

Via Benzinga

30 Stocks Moving In Friday's Mid-Day Session ↗

January 14, 2022

Gainers ATI Physical Therapy, Inc. (NYSE: ATIP) shares gained 25.2% to $3.8050 after Jefferies upgraded the stock from Hold to Buy and raised its price target from $3.50 to $5....

Via Benzinga

The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More ↗

December 06, 2021

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2021 ↗

November 09, 2021

Upgrades JP Morgan upgraded the previous rating for New Relic Inc (NYSE:

Via Benzinga

ADC Therapeutics to Participate in the Jefferies London Healthcare Conference

November 09, 2021

From ADC Therapeutics

Via Business Wire

ADC Therapeutics Announces Abstracts to be Presented at the 63rd ASH Annual Meeting

November 04, 2021

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics SA (ADCT) Q3 2021 Earnings Call Transcript ↗

November 03, 2021

ADCT earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

ADC Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates

November 02, 2021

From ADC Therapeutics SA

Via Business Wire

71 Biggest Movers From Yesterday ↗

November 03, 2021

Gainers Avis Budget Group, Inc. (NASDAQ: CAR) shares climbed 108.3% to close at $357.17 on Tuesday after the company reported better-than-expected Q3 adjusted EPS and sales...

Via Benzinga

ADC Therapeutics Announces Validation of its Marketing Authorization Application by the European Medicines Agency for ZYNLONTA®

October 29, 2021

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics to Host Third Quarter 2021 Financial Results Conference Call on November 2, 2021

October 27, 2021

From ADC Therapeutics SA

Via Business Wire

Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Pivotal Phase 2 Clinical Trial for Diffuse Large B-cell Lymphoma

September 29, 2021

From ADC Therapeutics

Via Business Wire

ADC Therapeutics Doses First Patient in Phase 1 Clinical Trial of ADCT-901 in Advanced Solid Tumors

September 27, 2021

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference

September 23, 2021

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics Receives Orphan Drug Designation in Europe for ZYNLONTA®

September 13, 2021

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics to Participate in Morgan Stanley’s 19th Annual Global Healthcare Conference

September 09, 2021

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics Announces Medical Leadership Transition

September 03, 2021

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics Announces $325M Financing Agreement With HealthCare Royalty ↗

August 26, 2021

ADC Therapeutics SA (NYSE: ADCT) has entered into a royalty purchase agreement with HealthCare Royalty Partners for up to $325 million. ADC Therapeutics...

Via Benzinga

ADC Therapeutics Enters Into a Financing Agreement with HealthCare Royalty for Up to $325 Million

August 26, 2021

From ADC Therapeutics SA

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2021 ↗

August 09, 2021

Upgrades DA Davidson upgraded the previous rating for AAON Inc (NASDAQ:

Via Benzinga

ADC Therapeutics SA (ADCT) Q2 2021 Earnings Call Transcript ↗

August 03, 2021

ADCT earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.